Vical's stock plunges 23% premarket after genital herpes treatment fails in phase 2 trial

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit or the quote page for more information about this breaking news.

Source: Market Watch

Leave a Reply

Your email address will not be published. Required fields are marked *